Latest Regulatory Progress News

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Dimerix has activated the first clinical trial site in Japan for its pivotal Phase 3 ACTION3 study targeting FSGS, triggering a significant milestone payment from its Japanese partner FUSO Pharmaceutical.

Epsilon Healthcare has emerged from Administration, securing expanded medicinal cannabis manufacturing permits and launching a new pharmacy brand as part of a strategic turnaround and growth plan.

Titanium Sands Limited has secured one-year retentions for four high-grade exploration licenses, enabling critical environmental studies and paving the way for a mining license application in Sri Lanka.

Battery Age Minerals has completed extensive exploration at its El Aguila Gold-Silver Project in Argentina, confirming free-milling gold and preparing for maiden drilling in the third quarter of 2025.

Medallion Metals has reported outstanding drilling results from its Kundip Mining Centre, reinforcing confidence in its resource base and growth potential. The company is also advancing exclusive talks to acquire the Forrestania Nickel Operation, a key step in its sulphide development strategy.

Neuren Pharmaceuticals has approved a significant long-term equity incentive plan tied to critical clinical and regulatory milestones for its drug candidate NNZ-2591, reinforcing management’s commitment to shareholder value.

Mineral Resources Limited has reported a significant expansion in the Onslow Iron Project’s Mineral Resources and Ore Reserves, underpinning its long-term growth strategy in iron ore production.

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

Southern Palladium has secured Environmental Authorisation for its Bengwenyama PGM Project, a crucial step toward mining rights and project development. The company is also refining a phased, lower-capital approach to unlock value and improve financeability.

Core Lithium has doubled the Grants Ore Reserve by shifting to underground mining, lifting total Finniss Ore Reserves to 10.73 million tonnes at 1.29% lithium oxide. This update supports a robust 10-year mine plan with potential for extended operations.